Cyteir Therapeutics focused on developing small-molecule therapeutics that target DNA Damage Response (DDR) pathways. This segment involved extensive research and development activities aimed at identifying and validating novel drug targets within the DDR network. The company's lead product candidate, CYT-0851, a first-in-class oral RAD51 inhibitor, was designed to exploit synthetic lethality in cancer cells. The therapeutic area covered by this segment was primarily oncology, with a focus on hematologic malignancies and solid tumors. The goal was to improve patient outcomes by selectively targeting cancer cells with impaired DNA repair mechanisms, offering a potential advantage over traditional chemotherapy. Future opportunities included expanding the pipeline with additional DDR-targeting agents and exploring combination therapies to enhance efficacy. Clinical trials were a crucial aspect of this segment, evaluating the safety and efficacy of CYT-0851 in various cancer types.